Medtronic has announced that the US Food and Drug Administration (FDA) has approved the Affera mapping and ablation system featuring the Sphere-9 Catheter. This innovative, all-in-one system ...

For more information on Affera and the Sphere-9 catheter, visit Medtronic.com. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's ...

GALWAY, Ireland - Medtronic plc (NYSE:MDT), a global healthcare technology leader, announced today that it has received FDA approval for its Affera Mapping and Ablation System with Sphere-9 Catheter.

Needham analyst Michael Matson has maintained their neutral stance on MDT stock, giving a Hold rating today. Michael Matson’s rating is ...

Today, vascular catheter-related bloodstream infections are the most serious and costly healthcare-associated infections. The purpose of this article is to describe the biofilm form of life ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Medtronic highlighted results from its PULSED AF clinical trial, which demonstrated the catheter isolated pulmonary veins with an average energy delivery time of 30 seconds. The device is designed ...

payment for the Medtronic Symplicity Spyral™ renal denervation (RDN) catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System.

Medtronic plc, a global leader in healthcare technology, announced the United States Food and Drug Administration (FDA) has approval of the Affera Mapping and Ablation System with Sphere-9 catheter, ...

The Affera Mapping and Ablation System and Sphere-9 catheter also received CE Mark in March 2023 and was approved in Australia in September 2024. In October 2024, Medtronic announced the start of ...